Our population-based cohort study demonstrates that >90% coverage in the first year of a universal 3 + 0 PCV program provided high population-level protection ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2018
• May 2018

The presence of Pseudomonas aeruginosa biofilms in lower airway specimens from cystic fibrosis (CF) patients is well established. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• January 2015

The National Human Papillomavirus (HPV) Vaccination Program in Australia commenced in 2007 for females and in 2013 for males, using the quadrivalent HPV... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• January 2015

We aimed to describe case of Influenza associated encephalitis/encephalopathy identified by the Australian Childhood Encephalitis study ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2017
• November 2017

To contextualise the ‘Australian & New Zealand Antifungal Consensus Guidelines, 2014, researchers surveyed current routine primary antifungal prophylaxis. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• March 2015

Globally, S. pneumoniae and H. influenzae remain the predominant otopathogens associated with OM as identified through bacterial culture ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2016
• January 2016

This study aims to address this evidence gap by assessing the clinical, physical, neurocognitive, economic and societal impact of invasive meningococcal disease ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2019
• December 2019

Respiratory syncytial virus contributes to significant global infant morbidity and mortality. We applied a previously developed statistical prediction model incorporating pre-pandemic RSV testing data and hospital admission data to estimate infant RSV-hospitalizations by birth month and prematurity, focused on infants aged <1 year. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• July 2023

Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season. Previous studies have shown that the nirsevimab binding site is highly conserved. However, investigations of the geotemporal evolution of potential escape variants in recent (ie, 2015–2021) RSV seasons have been minimal. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• July 2023

To assess parental awareness of respiratory syncytial virus (RSV) and the level of acceptance of future RSV prevention strategies. A cross-sectional online survey was implemented targeting "future" and "current" parents of children aged ≤5 years in Australia. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2024
• February 2024

Shortage of ear, nose, and throat specialists in public hospitals can result in delays in the detection and management of otitis media. This study introduced a new hospital-based telehealth service, named the Ear Portal, and investigated its role in improving access to specialist care. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• March 2023

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory syncytial virus vaccine or immunoprophylaxis remain highly active. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• January 2023